Maine insurance co-op sues over blocked CSRs

Health insurance co-op Maine Community Health Options (MHCO) has filed a lawsuit against the federal government over the Trump administration’s decision to stop making cost-sharing reduction subsidies, or CSRs.

Those payments were cut off by President Donald Trump in Oct. 2017, with HHS saying it couldn’t legally continue the payments without an appropriation from Congress. As reported by Talking Points Memo, MCHO said in its complaint that insurers still have to provide the subsidies to lower out-of-pocket costs for low-income enrollees, but no longer get reimbursed.

“This has caused Health Options and other [qualified health plan] issuers to suffer large financial losses,” the lawsuit staid. “It also leads to instability in the insurance markets and hinders Health Options’ and other (qualified health plan) issuers’ ability to design and price plans effectively for the ACA exchanges.”

MHCO is the largest individual market insurer in Maine. According to an earlier report by the Maine Bureau of Insurance, the co-op lost $1.9 million in Oct. 2017 alone due to the CSRs being cut off.

Soon after Trump’s decision, 19 states sued to get the payments quickly reinstated, but a federal judge turned down their request. The Congressional Budget Office has said funding the CSRs would actually reduce the federal deficit, since the resulting premium increases would mean more federal money spent on the ACA’s premium support subsidies, but Republicans have criticized CSRs as a “bailout” for insurers.

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.